DE602004027714D1 - Anti-tumor effekt von bik-mutanten - Google Patents

Anti-tumor effekt von bik-mutanten

Info

Publication number
DE602004027714D1
DE602004027714D1 DE602004027714T DE602004027714T DE602004027714D1 DE 602004027714 D1 DE602004027714 D1 DE 602004027714D1 DE 602004027714 T DE602004027714 T DE 602004027714T DE 602004027714 T DE602004027714 T DE 602004027714T DE 602004027714 D1 DE602004027714 D1 DE 602004027714D1
Authority
DE
Germany
Prior art keywords
bik
tumor effect
administered
polynucleotide
cancer therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027714T
Other languages
English (en)
Inventor
Mien-Chie Hung
Yan Li
Yong Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of DE602004027714D1 publication Critical patent/DE602004027714D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE602004027714T 2003-04-02 2004-04-02 Anti-tumor effekt von bik-mutanten Expired - Lifetime DE602004027714D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45990103P 2003-04-02 2003-04-02
PCT/US2004/010342 WO2004089981A2 (en) 2003-04-02 2004-04-02 Antitumor effect of mutant bik

Publications (1)

Publication Number Publication Date
DE602004027714D1 true DE602004027714D1 (de) 2010-07-29

Family

ID=33159707

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027714T Expired - Lifetime DE602004027714D1 (de) 2003-04-02 2004-04-02 Anti-tumor effekt von bik-mutanten

Country Status (8)

Country Link
US (3) US20050118154A1 (de)
EP (1) EP1611153B1 (de)
JP (1) JP2007524380A (de)
CN (1) CN100497382C (de)
AT (1) ATE471337T1 (de)
DE (1) DE602004027714D1 (de)
DK (1) DK1611153T3 (de)
WO (1) WO2004089981A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535315A (ja) 2004-04-02 2007-12-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌特異的プロモーター
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20090192101A1 (en) * 2006-11-22 2009-07-30 Mien-Chie Hung Cancer-specific promoters
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101827613A (zh) 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US8809392B2 (en) 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
EP2296696B1 (de) * 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Zusammensetzungen mit liposomen, einem antigen, einem polynucleotid und einem träger mit einer kontinuierlichen phase einer hydrophoben substanz
AU2012321022B2 (en) 2011-10-06 2017-03-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69112207T2 (de) 1990-04-05 1996-03-28 Roberto Crea "walk-through"-mutagenese.
US5641484A (en) 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
WO1993013216A1 (en) 1991-12-24 1993-07-08 The President And Fellows Of Harvard College Site-directed mutagenesis of dna
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
AU9402898A (en) * 1997-09-26 1999-04-23 Washington University Cell death agonists
US6190912B1 (en) * 1998-03-31 2001-02-20 Thomas Jefferson University Blk genes and uses thereof in apoptosis

Also Published As

Publication number Publication date
EP1611153B1 (de) 2010-06-16
WO2004089981A3 (en) 2005-01-20
WO2004089981A2 (en) 2004-10-21
US20090075885A1 (en) 2009-03-19
US8304526B2 (en) 2012-11-06
ATE471337T1 (de) 2010-07-15
US20110020431A1 (en) 2011-01-27
US20050118154A1 (en) 2005-06-02
DK1611153T3 (da) 2010-10-18
EP1611153A2 (de) 2006-01-04
CN1771259A (zh) 2006-05-10
CN100497382C (zh) 2009-06-10
JP2007524380A (ja) 2007-08-30

Similar Documents

Publication Publication Date Title
TW200612918A (en) Lonidamine analogs
WO2004087068A3 (en) Cxcr4 antagonists and methods of their use
DE60221234D1 (de) Verwendung von füllstoffe als sättigungsmittel
DE60231439D1 (de) Mitotische kinesinhemmer
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
SI1663242T1 (sl) 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE443724T1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
DE60025812D1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
ATE471337T1 (de) Anti-tumor effekt von bik-mutanten
NO20050640L (no) Rutenium anticancer komplekser
DK1390371T3 (da) Oxazolo- og furopyrimidiner samt deres anvendelse i lægemidler mod tumorer
DE60128701D1 (en) Claudin polypeptide
ATE356810T1 (de) Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
ATE294793T1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
NO20053903D0 (no) Nukleotidlipidesterderivater.
ATE315029T1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
DE60026046D1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
IL149416A0 (en) Human enzymes of the metalloprotease family
ATE411036T1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
ZA98420B (en) Use of pramipexole in the treatment of restless legs syndrome.